tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ACRS Stock Latest News

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Press ReleasesAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
3d ago
ACRS
Aclaris announces first patient dosed in Phase 2a trial of ATI-2138
PremiumThe Fly
Aclaris announces first patient dosed in Phase 2a trial of ATI-2138
3d ago
ACRS
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
PremiumPress Releases
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
10d ago
ACRS
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
PremiumPress Releases
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
1M ago
ACRS
Aclaris Therapeutics expects cash to fund operations into 2028
PremiumThe Fly
Aclaris Therapeutics expects cash to fund operations into 2028
1M ago
ACRS
Aclaris Therapeutics reports Q2 EPS (15c), consensus (20c)
PremiumThe FlyAclaris Therapeutics reports Q2 EPS (15c), consensus (20c)
1M ago
ACRS
Is ACRS a Buy, Before Earnings?
Premium
Pre-Earnings
Is ACRS a Buy, Before Earnings?
1M ago
ACRS
Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties
Premium
Company Announcements
Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties
2M ago
8K
ACRS
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PremiumPress Releases
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
4M ago
ACRS
Aclaris Therapeutics Corporate Update Conference Call
PremiumCompany Announcements
Aclaris Therapeutics Corporate Update Conference Call
5M ago
8K
ACRS
Aclaris Therapeutics reports Q1 EPS (24c), consensus (29c)
PremiumThe Fly
Aclaris Therapeutics reports Q1 EPS (24c), consensus (29c)
5M ago
ACRS
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
PremiumPress Releases
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
5M ago
ACRS
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
PremiumCompany AnnouncementsBoard Changes Ahead of Aclaris Therapeutics Annual Meeting
6M ago
8K
ACRS
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Premium
Press Releases
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
7M ago
ACRS
Aclaris Therapeutics reports Q4 EPS (2c), consensus (34c)
Premium
The Fly
Aclaris Therapeutics reports Q4 EPS (2c), consensus (34c)
7M ago
ACRS
Aclaris Therapeutics Executive Team Undergoes Major Changes
PremiumCompany Announcements
Aclaris Therapeutics Executive Team Undergoes Major Changes
8M ago
8K
ACRS
Aclaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Aclaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
8M ago
ACRS
Aclaris Therapeutics Announces Executive Leadership Changes
PremiumMarket News
Aclaris Therapeutics Announces Executive Leadership Changes
8M ago
8K
ACRS
Aclaris Therapeutics conducting strategic review of business
PremiumThe Fly
Aclaris Therapeutics conducting strategic review of business
8M ago
ACRS
Aclaris Therapeutics CEO Douglas Manion to step down
PremiumThe FlyAclaris Therapeutics CEO Douglas Manion to step down
8M ago
ACRS
Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
Premium
The Fly
Aclaris Therapeutics downgraded to Neutral from Buy at BTIG
8M ago
ACRS
Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
Premium
The Fly
Aclaris downgraded to Hold at Jefferies after ATI-1777 data reported
8M ago
ACRS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >